By Chen Ke

Recently, a famous domestic biopharmaceutical company which is building a production base in Nantong Economic & Technological Development Area, Biotheus Inc. has reached an equity acquisition agreement with BioNTech, a global pharmaceutical giant from Germany.

According to the agreement, BioNTech will acquire 100% of Biotheus' issued share capital with an advance payment of $800 million. The deal is expected to be completed in the first quarter of 2025.

Biotheus (Nantong) Co., Ltd., as an important part in the building of a complete industrial chain for antibody new drug development of Biotheus Inc., has a 61,000 square meters industrialized production base that meets international standards in Nantong Economic & Technological Development Area, which takes on the responsibility of the group’s industrial production. After the completion of this equity acquisition, Biotheus (Nantong) will continue to take root in Nantong Economic & Technological Development Area, and build a first-class biopharmaceutical production base. At the same time, Biotheus (Nantong) will function as the only industrial production base of BioNTech in China at present, to make contributions to its global products’ production and supply.

BioNTech is a Fortune Global 500 company which is leading in mRNA vaccine research and development in the world. It is dedicated to developing a new generation of immunotherapies for cancer and other major diseases.